ClinicalTrials.gg
CompletedNCT04289454Updated Mar 21, 2022

Sensory Analysis and Taste Modulation of Ketone Esters

An interventional study of Flavor additive in Flavor Perception in Normal, Healthy Adults, sponsored by Monell Chemical Senses Center. Completed at 1 site in United States. Open to participants aged 21 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-03-21.

Sponsored by Monell Chemical Senses Center · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
19
Allocation
Not applicable
Ages
21 Years to 45 Years
Sex
All
01

Study summary

Ketone ester (KE) drinks are sold commercially in the USA and elsewhere (the FDA has accepted a GRAS (generally regarded as safe) notification on the KEs we propose to study). KE drinks can have beneficial effects on metabolism. Unfortunately, KE drinks have a strongly unpleasant flavor which can trigger rejection. The current study will generate data to help inform KE drink formulations with improved flavor. First stage, trained subjects will rate the intensity of various sensation qualities (e.g., bitter, sour, metallic, and astringent) from KE drinks to help understand the nature of the unpleasant flavor and the particular sensory systems involved (e.g., taste vs. smell). Then, subjects will taste KE drinks with and without various flavor modifiers. Subjects will be healthy adults (aged 21-45) without known food allergies.

02

Conditions studied

  • Flavor Perception in Normal, Healthy Adults
03

In context

Lead sponsor

Monell Chemical Senses Center is the lead sponsor of 18 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Good general health (self report)
  2. Men and women
  3. Age from 21 to 45

Exclusion criteria

Exclusion Criteria:

  1. Current (or within the last four weeks) acute illness, such as cold or flu
  2. Currently active allergies
  3. Regular use of medication (over the counter or prescription), except for birth control.
  4. Any history of food allergy or sensitivity (particularly to KE drinks or MSG). Any history of sensitivity to 6-Propylthiouracil (bitter compound frequently used to assess individual differences in sensitivity to bitterness).
  5. Pregnant, nursing, or trying to become pregnant during the study (pregnancy can affect flavor perception)
  6. Chronic illness (any ongoing condition that is serious or required medical monitoring), including kidney problems, liver problems, cardiovascular problems (e.g., heart disease or high blood pressure), diabetes, HIV infection, or other ongoing illness). Diabetes or other metabolic issues could be important for safety as well as quality of data.
  7. History of taste problems (absent or abnormal sense of taste)
  8. Weigh less than 100 pounds (45.4 kilograms). This is to help ensure that the amount of KE drink consumed remains below the single serving in the GRAS (generally regarded as safe) notice which the FDA has accepted.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Other
    Effect of flavor modifiers

    Intervention in the study: Subjects will taste model KE drinks with (control condition) and without (experimental condition) added flavors. Design is within-subjects (subjects will taste both the experimental and control drinks), with order counter-balanced across subjects.

    Other: Flavor additive

Interventions

  • OtherFlavor additive

    Various flavor additives will be tested (vs. no added flavor) to determine which show promise for making KE drinks taste less unpleasant

06

What researchers measure

Primary outcomes

  1. Rated intensity profile

    Rated intensity of taste qualities (e.g., sour, bitter) and mouth-feel (astringent) of model drinks, measured using the general Labeled Magnitude Scale (gLMS). In this implementation of the gLMS, scores will range from 0 (or "no sensation") up to 100 ("strongest imaginable sensation"), with higher scores indicating stronger perceived intensity for the sensation in question.

    Time frame: Through study completion (up to a year for a given participant, depending on how many drink samples the participant agrees to evaluate). Participants will rate the intensity of about 12 model drink samples during each study visit.

Secondary outcomes

  1. Hedonic response

    Ratings of how likely the flavor of each sample tasted would be to discourage use of a product with that flavor, assuming the rater otherwise wanted associated nutritional or performance benefits

    Time frame: Through study completion (up to a year for a given participant, depending on how many drink samples the participant agrees to evaluate). Participants will rate the pleasantness of about 12 model drink samples during each study visit.

  2. Rated upper GI symptoms

    Rated intensity of nausea, bloating, and heartburn, using a nine-point category scale (some bitter liquids can trigger mild to moderate feelings of nausea). Scores for each symptom range from 0 ("none") to 8 ("Unbearable"), with "mild" (2), "moderate" (4), and "severe" (6) as labeled intermediate categories.

    Time frame: Through study completion (up to a year for a given participant, depending on how many drink samples the participant agrees to evaluate). Participants will rate upper GI symptoms after tasting about 12 model drink samples during each study visit.

07

Study locations

1 site
  • Monell Chemical Senses Center
    Philadelphia, Pennsylvania 19014, United States
08

References and documents

Study documents

  • Informed consent form · Jan 19, 2022

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Undecided — If individual subject data are shared, the data will be de-identified first (no identifying information will be shared with other researchers).

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2020 to primary completion in Jun 2021, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2020
First posted
Feb 28, 2020
StartActual
Aug 30, 2020
Primary completionActual
Jun 4, 2021
CompletionActual
Jun 4, 2021
Last update
Mar 21, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04289454
Lead sponsor
Monell Chemical Senses Center
Collaborators
HVMN (funding; holder of primary Department of Defense STTR contract)
Responsible party
Paul Wise (Associate Member (equivalent to Associate Professor), Monell Chemical Senses Center) — Principal investigator
First posted
Feb 28, 2020
Start date
Aug 30, 2020
Primary completion
Jun 4, 2021
Completion
Jun 4, 2021
Last update
Mar 21, 2022

Study contacts

Paul M Wise, PhD
principal investigator · Monell Chemical Senses Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion